PEPTIDEREPORT

Telehealth company

Hims & Hers

Official weight-loss program page reviewed

Unclaimed profileReviewed Jul 10, 2026
Visit official siteClaim this profile

Telehealth service profile

Care model
Online weight-management membership
Medication access
Prescription options may include GLP-1 medicines when clinically appropriate and available.
Provider model
Consultation and ongoing care through licensed providers
Pharmacy pathway
Fulfillment depends on the prescribed treatment and program terms.
Insurance support
Program and medication pricing vary; coverage is not assumed.
Availability
Eligibility and treatment options depend on clinical review and location.

Linked public records

Regulatory actions

FDA Agency statement

FDA announces intent to act against mass-marketed non-approved compounded GLP-1 drugs

Intent announced · Policy statement

FDA announced intended enforcement steps involving GLP-1 active pharmaceutical ingredients used in mass-marketed non-approved compounded drugs and misleading direct-to-consumer promotion. The statement named Hims & Hers among the companies in scope but was not itself a final adjudication against that company.

Compounds: Semaglutide, Tirzepatide

View linked recordPrimary source

Editorial record

Medication availability, eligibility, pricing, and fulfillment can change and require confirmation during the clinical intake process.

Profile ownership: unclaimed. Company representatives will be able to propose identity and catalog updates without changing editorial or regulatory records.

Official sources

Official source 1